These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 1458463)
61. Selective killing of leukemia and lymphoma cells ectopically expressing hCGbeta by a conjugate of curcumin with an antibody against hCGbeta subunit. Vyas HK; Pal R; Vishwakarma R; Lohiya NK; Talwar GP Oncology; 2009; 76(2):101-11. PubMed ID: 19127081 [TBL] [Abstract][Full Text] [Related]
62. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Appelbaum FR; Matthews DC; Eary JF; Badger CC; Kellogg M; Press OW; Martin PJ; Fisher DR; Nelp WB; Thomas ED Transplantation; 1992 Nov; 54(5):829-33. PubMed ID: 1440849 [TBL] [Abstract][Full Text] [Related]
63. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715 [TBL] [Abstract][Full Text] [Related]
64. Preparation and characterization of a chimeric CD19 monoclonal antibody. Zola H; MacArdle PJ; Bradford T; Weedon H; Yasui H; Kurosawa Y Immunol Cell Biol; 1991 Dec; 69 ( Pt 6)():411-22. PubMed ID: 1725979 [TBL] [Abstract][Full Text] [Related]
65. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. Benedict CA; MacKrell AJ; Anderson WF J Immunol Methods; 1997 Feb; 201(2):223-31. PubMed ID: 9050944 [TBL] [Abstract][Full Text] [Related]
66. Monoclonal antibodies in the treatment of myelogenous leukemias. Scheinberg DA Cancer Treat Res; 1993; 64():213-32. PubMed ID: 7680876 [No Abstract] [Full Text] [Related]
67. Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias. Li S; Shen D; Guo X; Liao C; Tang Y DNA Cell Biol; 2018 Sep; 37(9):778-785. PubMed ID: 30096000 [TBL] [Abstract][Full Text] [Related]
68. Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen. Fogler WE; Sun LK; Klinger MR; Ghrayeb J; Daddona PE Cancer Immunol Immunother; 1989; 30(1):43-50. PubMed ID: 2598174 [TBL] [Abstract][Full Text] [Related]
69. Effects of methocel A15LV, polyethylene glycol, and polyvinyl alcohol on CD13 and CD33 receptor surface content and metabolism of HL60 cells cultured in stirred tank bioreactors. McDowell CL; Carver RT; Papoutsakis ET Biotechnol Bioeng; 1998 Oct; 60(2):251-8. PubMed ID: 10099426 [TBL] [Abstract][Full Text] [Related]
70. A human T cell line engineered to secrete chimeric monoclonal antibody. Tsang KY; Kashmiri SV; De Filippi R; Qi CF; Calvo B; Shu L; Nieroda CA; Greiner JW; Schlom J J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):143-52. PubMed ID: 8471589 [TBL] [Abstract][Full Text] [Related]
71. Identification of the block in targeted retroviral-mediated gene transfer. Zhao Y; Zhu L; Lee S; Li L; Chang E; Soong NW; Douer D; Anderson WF Proc Natl Acad Sci U S A; 1999 Mar; 96(7):4005-10. PubMed ID: 10097153 [TBL] [Abstract][Full Text] [Related]
73. Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases. Xu Z; Jin H; Qian Q Expert Opin Ther Pat; 2009 Jul; 19(7):1035-7. PubMed ID: 19552516 [TBL] [Abstract][Full Text] [Related]
74. Human and humanized monoclonal antibodies: preclinical studies and clinical experience. Ostberg L; Queen C Biochem Soc Trans; 1995 Nov; 23(4):1038-43. PubMed ID: 8654677 [No Abstract] [Full Text] [Related]
75. [Molecular-targeted drugs. 1) Indications and the application of molecular-targeted drugs in hematological diseases]. Okawa Y; Aiba K Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1908-17. PubMed ID: 19894352 [No Abstract] [Full Text] [Related]
76. Is inherent disclosure sufficient for priority claim? Monoclonal versus chimeric/humanized antibody: estoppels. Komatani TS Pharm Pat Anal; 2016 Sep; 5(6):375-376. PubMed ID: 27848274 [No Abstract] [Full Text] [Related]
77. HuM195 and its single-chain variable fragment increase Aβ phagocytosis in microglia via elimination of CD33 inhibitory signaling. Wong E; Malviya M; Jain T; Liao GP; Kehs Z; Chang JC; Studer L; Scheinberg DA; Li YM Mol Psychiatry; 2024 Jul; 29(7):2084-2094. PubMed ID: 38383769 [TBL] [Abstract][Full Text] [Related]
78. Targeting acute myeloid cell surface using a recombinant antibody isolated from whole-cell biopanning of a phage display human scFv antibody library. Sumphanapai T; Chester K; Sawatnatee S; Yeung J; Yamabhai M Med Oncol; 2022 Sep; 39(12):205. PubMed ID: 36175701 [TBL] [Abstract][Full Text] [Related]
79. ImmunoPET, [ Srideshikan SM; Brooks J; Zuro D; Kumar B; Sanchez J; Echavarria Parra L; Orellana M; Vishwasrao P; Nair I; Chea J; Poku K; Bowles N; Miller A; Ebner T; Molnar J; Rosenthal J; Vallera DA; Wong JYC; Stein AS; Colcher D; Shively JE; Yazaki PJ; Hui SK Clin Cancer Res; 2019 Dec; 25(24):7463-7474. PubMed ID: 31548348 [TBL] [Abstract][Full Text] [Related]
80. Radiopharmaceuticals for Relapsed or Refractory Leukemias. Kunos CA; Capala J; Ivy SP Front Oncol; 2019; 9():97. PubMed ID: 30859091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]